Jefferies Maintains Buy on Amylin Pharmaceuticals

Jefferies is out with its report today on Amylin Pharmaceuticals AMLN, maintaining Buy. In a note to clients, Jefferies writes, "We viewed AMLN's presentations on QT data from DURATION-1 and new data on Byetta once monthly as incremental positives for the stock. We also see the undisclosed safety issue at the 3mg dose of Lilly's LLY dulaglutide as another incremental positive for AMLN." Jefferies maintains a $22 PT on AMLN. Shares of AMLN closed Friday at $11.83, down 2.39% from Thursday's close.